The mean age of our patients was 50 years, and 15.5% had a family history of breast cancer. The mean tumor size was 43.8 mm. Histological examination revealed invasive ductal carcinoma in 88.9% of the cases, metaplastic carcinoma in 5.6%, and medullary carcinoma and adenoid cystic carcinoma in 2.2%. BLBC was most often associated with a high tumor grade (55.3% had a grade 3 tumor) and a high Ki-67 proliferative index. Vascular invasion was found in 31.1% of the cases. Regarding lymph node involvement, 42.9% had positive lymph nodes and 7.9% featured distant metastases. Surgical treatment was provided for 85 patients. It consisted of conservative surgery in 40 cases and radical surgery in 45 cases. Neoadjuvant chemotherapy was administrated to 23 patients, with a 13% complete pathologic response. The rates of overall survival and disease-free survival at 3 years for localized BLBC were 74.4% and 75.9%, respectively.
The various molecular subtypes of breast cancer include luminal A and B, marked by overexpression of estrogen receptor (ER) and its targets in the luminal epithelial layer of the mammary gland; human epidermal growth factor receptor 2 (HER2/ErbB2)-positive subtype, characterized by 2 clinical outcomes. However, as standard microarraybased transcriptional profiling is not currently feasible in the clinic, immunohisto-chemistry provides a more practical approach to determining various subtypes of breast cancer by identifying 3, 4 protein products of the signature genes. Human breast tumors can be classified at the molecular level, with each molecular subtype being characterized by distinctive gene signatures and
Variables
The aim of our study was to determine the clinicopathological, therapeutic, and prognostic features associated with this type of breast cancer in the Tunisian population.
Methods
Overall survival (OS) was defined as the interval between the date of diagnosis and either death or the date of the last follow-up. The other end point considered was disease-free survival (DFS), defined as the length of time from the date of diagnosis to the date of the first signs of progress confirmed by the investigator in the medical record, the date of death, or date of most recent news when the patient was high expression of the HER2 oncogene; and triplenegative subtype, defined by negative expression of 2 genes coding for estrogen, progesterone, or HER2.
A subset of triple-negative cancers, distinguished by expression of genes characteristic of the outer or basally located epithelial layer of the mammary gland such as cytokeratin (CK) 5 and 17 and the epidermal growth factor receptor (EGFR/HER1), is classified as basal-like breast cancer (BLBC).5 BLBC is associated with an unfavorable clinical profile with a high risk of early metastatic relapse. Furthermore, currently there is no targeted treatment for BLBC, and the only validated systemic therapy is chemotherapy. Despite the use of recent patterns of chemotherapy, the prognosis remains poor, 3 representing a challenge in clinical practice.
Study population
In a retrospective cohort study, we reviewed a total of 4120 breast cancer cases with complete immunohistochemical analysis registered in Salah Azaiez Institute of Cancer between January 2009 and December 2013. Only triple-negative breast cancer (TNBC) cases were eligible for inclusion in the study. Cases were excluded if there was no expression of basal markers (CK5/6), the patient was deceased, or had lost her eyesight.
The epidemiological, clinicopathological, therapeutic, and evolutive data were analyzed. The basal-like tumors in our study were defined by the absence of ER and PR expression, and the lack of high HER2 expression (a HER2 score of ≤ 2, with 2 negative FISH testing). Cancer staging was carried out based on the TNM system. In patients who had undergone upfront surgical treatment, cancer staging was based on pathological findings; however, for cases receiving neoadjuvant chemotherapy, clinical and radiologic staging was performed.
Tumors were graded using the Scarff-BloomRichardson (SBR) histological system. Sataloff and Chevalier's pathological classification was chosen as the primary end point in the assessment of histological response in both the mammary gland and axillary lymph nodes.
The metastases were especially visceral in the first position. Bone metastases accounted for 25%.
The majority of patients (85.6%) had an infiltrating ductal carcinoma, 2.2% had medullary carcinoma, 5.6% had metaplastic carcinoma and others histologic subtypes were identified in 6.6% of cases. Tumors were poorly differentiated and had high proliferation indexes, with 47 (55.3%) cases being grade 3 and 33 (44.7%) cases being grade II, with a mean Ki-67 index of 49%. Regarding lymph node involvement, 42.9% of patients had positive l y m p h n o d e s a t i n i t i a l d i a g n o s i s , a n d a lymphovascular invasion was found in 31.1% of cases.
As for disease stage, 10.1% were classified as stage I, 53.9% stage II, 28.1% stage III, and 7.9% (n = 8) stage IV at first diagnosis. Almost half of the patients (51.1%) had a T2 tumor.
Forty-four patients were menopausal (48.9%). Fourteen patients reported having at least one firstor second-degree relative with breast cancer. The identification of BRCA mutation was not performed in any patient.
Based on the immunohistochemical study, all the tumors had a triple-negative basal-like phenotype defined by lack of expression of the ER, PR, and Table 2 illustrates the main clinicopathological characteristics of the study population. Combined m a m m o g r a p h y a n d u l t r a s o u n d s h o w e d abnormalities in 97.5% of patients, of whom 72.5% had lesions that were highly suspicious of malignancy (BI-RADS category 5). Only 2.5% were known to be probably benign lesions (BI-RADS 3) and were then reclassified.
Clinicopathological characteristics
Of the 4120 cases reviewed, 300 (11.3%) were TNBC, of which 90 (30%) expressed basal-like markers on immunohistochemistry and therefore were included in the study.
Results
The frequencies of risk factors for breast cancer in our study sample are shown in Table 1 . The median age at diagnosis was 50 years (range: 24-91 years; <40 years = 21%, 40-59 years = 21%, >60 years = 58%).
Statistical analyses
censored.
The statistical analysis was performed using SPSS 21.0. Descriptive statistics (frequencies for qualitative variables and minimum, maximum, mean and SD for quantitative variables) were used to summarize clinical data and demographics of the patients. Estimations of the OS and FDS functions S (t) at 3 and 5 years were performed according to the Kaplan-Meier analysis and the log-rank test with stratification of our study population into 2 groups: localized and metastatic disease. 
After a median follow-up of 49 months, 12 of the 82
Radiation therapy was indicated in 69 nonmetastatic patients. Palliative radiotherapy was delivered in 2 patients with painful bone metastasis.
As for treatment modalities, 85 (94.4%) patients received surgery, of whom 40 had conservative surgery (tumorectomy with axillary lymph node) and 45 received radical mastectomy with axillary lymph node dissection (Patey type mastectomy). Histological margins were clear in all patients with local disease.
Of 68 patients who had received adjuvant chemotherapy, 17 (25%) had anthracycline-based chemotherapy, and 35 (51.5%) had anthracycline followed by taxane. The 8 patients with metastatic disease had received an anthracycline-based regimen as the first-line for patient with metastatic diseases.
Treatment details and outcomes nonmetastatic patients experienced locoregional
Six patients of the 8 with metastatic disease at diagnosis experienced progression, and two patients responded to palliative treatment with tumoral stability and then progression. All the metastatic cases died with a median survival of 12.5 months (range [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .Of the 23 patients who had advanced tumors or inflammatory breast cancer, 19 had received anthracycline and 4 had received a n t h r a c y c l i n e p l u s t a x a n e n e o a d j u v a n t chemotherapy. Only 3 (13%) patients had a pathologic complete response (pCR) following neoadjuvant chemotherapy according to Sataloff and Chevalier's classification.
OS at 3 and 5 years were respectively 74.4% and 61.9% (Figure 1 ). After exclusion of patients diagnosed at a metastatic stage, OS raised to 81.9% at 3 years and 67.2% at 5 years ( Figure 2) . DFS rate for patients with localized disease was 75.9% at 3 years and 67% at 5 years ( Figure 3 ). relapse and 19 patients had a metastatic recurrence. The maximum of recurrence occurred between the first and second year after diagnosis, with a median of 21 months, and 24 patients died. 
Discussion
In our work, however, the basal-like phenotype represented only 30% of TNBC, which is not in accordance with the literature. In fact, 80% of TNBC have a basal-like phenotype (TN-BL) and the remaining 20% are defined as TN non-basal-like 11 (TN-non-BL) tumors. BLBCs were reported to present at a younger age compared with other 7 subtypes (53 vs 58 years). The median age at diagnosis (50 years) in our study was younger than the average age mostly reported in the US population 6, 9, 12 but close to the median age in Hispanic patients.
Clinically, BLBC patients presented with large tumors with a mean tumor size of 43.87 mm and a high rate of nodal involvement (42.9%). Studies suggest that lower incidence of microcalcifications and peritumoral ductal carcinoma in situ may represent typical mammographic characteristics of 16, 17 BLBC. Because of its more aggressive biology, BLBC often manifests itself as an interval cancer (detected within 12 months after a normal screening 18 mammogram). Histologically, basal-like tumors in our study were characterized by a high frequency of ductal histology (88.9%), greater histological grade (55.3%), and lymphovascular invasion (31.1%), 3, 5, 19, 20 which are in accordance with the literature.
We analyzed the epidemiological, clinical, and therapeutic characteristics of BLBC in a sample of Tunisian patients. The demographic and clinical features of our sample were, to a large extent, [6] [7] [8] [9] consistent with the literature. The frequency of TNBC reported in the present work (11.3%) agrees 7 with the previous reports (10%-17%). In the Chinese population, approximately 12.9% of breast 10 cancers are TNBC.
Currently, there is no approved targeted therapy available for BLBC. Both adjuvant treatment and palliative therapy are limited to chemotherapy. TNBC generally has higher pCR rates than non-TNBC, and TNBC patients achieving pCR have better survival compared with TNBC patients who 21 do not achieve pCR. The higher rate of response to More than half of the subjects in our study (59%) were 40 to 59 years old, suggesting that there might be factors predisposing towards the development of this disease. BLBC occurs more frequently in premenopausal women compared with other breast 13 cancer subtypes. In the current study, patients were premenopausal in 51.1% of cases. We found a 71.5% rate of family history of breast cancer in our cases. Unfortunately, data regarding BRCA1/2 gene mutations were not available. Given that 20% of BLBC had mutations in BRCA in the literature, the basal-like type may be used as a criterion for genetic screening to improve the prognosis of this aggressive molecular subtype through a diagnosis at an early stage and the sensitivity of BRCA1-mutant TN- 3, 14, 15 BLBC to PARP inhibitors.
Moreover, currently there is no targeted therapy available for this subtype of breast cancer. Therefore, novel molecular targets and tumor response to various treatments are open avenues of investigation. Also, since BLBC is perplexingly heterogeneous, research should strive to identify novel prognostic markers to aid in improving disease management in this population.
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In the metastatic setting, the prognosis is extremely worse. It represented an aggressive entity associated with very rapid progression and mortality. The most common sites for BLBC metastases are the 26 lungs, liver, and central nervous system.
Research suggests that cell cycle and DNA damage response are highly activated in BLBC and that tumor cells are results of defects in the homologous recombination repair system. Therefore, they are vulnerable to platinum salts or 14, 27 PARP inhibitors. However, we have to wait for the outcome of several current clinical studies in order to define the correct strategy for the management of [28] [29] [30] BLBC.
Prognosis of BLBC remains pejorative compared with other subtypes. TN-BL tumors usually display 10 aggressive metastatic behavior. These tumors respond to conventional chemotherapy but recur more frequently than hormone receptor-positive, 7 luminal subtypes and have a high mortality rate. In our series, 3-and 5-year survival rates were 81.9% and 67.2%, respectively. These results are similar to those reported by Liedtke et al. in 1118 patients over 23 a 20-year period (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) . BLBC is also associated with a higher risk of relapse when compared with other molecular subtypes, especially 24 during the first 2-3 years of follow-up. Dent et al. reported that the risk of recurrence in BLBC patients 7 peaked 1 to 3 years from the date of diagnosis. In the study of Luedtke et al., DFS rates at 1 and 3 years were 81% and 63%, respectively, for BLBC in localized stages compared with 90% and 76% for 2 5 other molecular subgroups. In our study population, DFS rates at 3 and 5 years were 75.9% and 67%, respectively. neoadjuvant chemotherapy may be due to the typically high tumor grade and mitotic index of 3, 22 BLBC. However, it seems that only TN non-BLBC 14 tumors achieve a pCR. In fact, in our series, pCR rate was 13% after neoadjuvant chemotherapy based on the classification of Sataloff and Chevalier.
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